Browsing by Author "Juan Patricio Nogueira"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
    (2024-07-05) Walter Masson; Martín Lobo; Juan Patricio Nogueira; Alfredo Matias Rodriguez-Granillo; Leandro Ezequiel Barbagelata; Daniel Siniawski
    The anti-inflammatory effect of semaglutide may represent one of the mechanisms underlying its cardiovascular benefits in patients with type 2 diabetes mellitus and/or obesity. This systematic review and meta-analysis, conducted according to PRISMA guidelines, evaluated randomized clinical trials assessing the effect of semaglutide on C-reactive protein (CRP) levels compared with placebo or other glucose-lowering therapies. Thirteen randomized clinical trials involving 26,131 participants were included. Semaglutide was associated with significantly lower CRP levels compared with both placebo and control groups, regardless of treatment regimen or population evaluated. These findings support a significant anti-inflammatory effect of semaglutide that may contribute to its cardiovascular benefits.
  • No Thumbnail Available
    Item
    Estratificación del riesgo cardiovascular en pacientes con obesidad – Parte I
    (2026-04-01) José Silveyra; Jorge Riera Stival; Marianella Aguirre Ackermann; María Virginia Busnelli; Ana María Cappelletti; Gustavo Alcalá; Emiliano Salmeri; Matías Arrupe; Sergio Giménez; Alicia Elbert; Guillermo De’Marziani; Melania Pajón; Juan Patricio Nogueira; Pablo Corral; Carolina Chacón; Carolina Gianoli; Ezequiel Forte; Bautista Soumoulou; Miguel Schiavone; Gustavo Lavenia; Paola Harwicz; Paula Pérez Terns
    La obesidad es una enfermedad crónica de prevalencia creciente y un importante factor de riesgo cardiovascular (RCV). Debido a la heterogeneidad de sus fenotipos clínicos y metabólicos, su evaluación debe trascender el índice de masa corporal (IMC). Este consenso intersocietario sintetiza la evidencia disponible y formula recomendaciones prácticas para evaluar y abordar el RCV en personas con obesidad. Un panel multidisciplinario revisó guías clínicas, estudios epidemiológicos, ensayos clínicos y metanálisis, aplicando el sistema GRADE. La estratificación integral debe considerar adiposidad central, puntajes de riesgo validados, comorbilidades cardiometabólicas y daño orgánico clínico y subclínico para orientar estrategias preventivas y terapéuticas personalizadas.
  • No Thumbnail Available
    Item
    Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    (2024-03-10) Fernando Bril; Gabriela Berg; Magali Barchuk; Juan Patricio Nogueira
    Dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist and substantially increase cardiovascular risk. This review examines their pathophysiological relationship and current therapeutic approaches. Insulin resistance plays a central role in both conditions, supporting an integrated strategy targeting lipid abnormalities, glycemic control, body weight, and liver disease. Lifestyle interventions remain fundamental, while lipid-lowering and glucose-lowering therapies provide complementary cardiometabolic benefits. Statins are safe and recommended when clinically indicated, whereas emerging therapies may simultaneously improve liver disease and lipid profiles. Comprehensive management of MASLD and dyslipidemia is essential to reduce cardiovascular risk and optimize metabolic and hepatic outcomes in affected patients.